Non-invasive forced expiratory flow-volume curves to measure lung function in cats.

Forced expiratory flow-volume curves were performed in 15 cats using the non-invasive thoracic compression techniques developed for use in human infants. Cats breathed through a face mask and pneumotachygraph from which flow and volume were obtained. Thoracic compression was applied from an inflatable bag in a non-expandable jacket surrounding the animal. Bag inflation at end inspiration was initiated by a computer pulse to a pressurized chamber. Processed signals from the pneumotachygraph determined maximum-forced expiratory flow at lung volume equivalent to functional residual capacity (FRC), termed V'maxFRC. Different compression pressures were used, and the highest value from a technically satisfactory flow-volume loop was taken as the result. Mean (+/- 95% CI) V'maxFRC was 422 (369-475) ml/s. Compared with infants of similar weight (V'maxFRC approximately 180 ml/s), cats had a much higher V'maxFRC. Tests repeated another day showed a mean (+/-95% CI) percentage difference between paired tests to be 2.8 (-12.6, +18.3)%. Non-invasive forced expiratory flow-volume measurements can be reliably obtained in sedated cats.

Non-invasive measurement of total respiratory compliance and resistance in cats.

We adapted non-invasive techniques developed for human infants to measure total respiratory system compliance (Crs) and resistance (Rrs) in 21 healthy cats. The animals breathed through a face mask attached to a respiratory circuit and measurements were taken of changes in lung volume and airway pressure during brief occlusions of the airway at different lung volumes. The slope of the plot of change in volume against airway pressure yielded the multiple occlusion Crs with a mean (+/-95%CI) value of 6.8 (6.3-7.3) ml/cm H2O. In 12 animals measurements were made by the single breath technique in which occlusion was made early in expiration and on release, a plot of the subsequent relaxed expiratory flow and volume yielded the time constant (taurs), Crs and Rrs with mean (+/-95%CI) values of 0.27 (0.22-0.31) s, 7.0 (6.1-7.8) ml/cm H2O, and 38.7 (33.7-43.6) cm H2O/l/s, respectively. Rrs was significantly correlated inversely with forced expiratory flow at resting lung volume (V'maxFRC).

The use of the Objective Structured Clinical Examination (OSCE) in small-animal internal medicine and surgery.

The Objective Structured Clinical Examination (OSCE) has been used extensively to evaluate clinical skill of medical students. This article reports on its adaptation to veterinary medicine.

Down-regulation of MHC class II receptors of DH82 cells, following infection with Ehrlichia canis.

In order to evaluate whether infection with E. canis alters the expression of major histocompatibility complex (MHC) class I and/or MHC class II receptors, and by doing so alters the immune response to the organism, flow cytometry was performed on DH82 cells infected with Ehrlichia canis (90% infection) and on uninfected DH82 cells of the same passage, using anti-canine MHC class I and II antibodies. MHC class II expression was evident in 47.6 and 46.2% (mean 46.9%) of uninfected DH82 cells using two different anti-MHC class II antibodies, while no MHC class II expression was evident in DH82 cells infected with E. canis. The present results indicate that infection of DH82 macrophages with E. canis down-regulates their MHC class II receptors. These results suggest a possible mechanism by which E. canis evades the immune system.

Evaluation of doramectin for the treatment of experimental canine spirocercosis.

The nematode Spirocerca lupi is primarily a parasite of dogs, which causes typical lesions of esophageal nodular granulomas, aortic aneurysms and spondylitis. In order to evaluate the therapeutic effect of doramectin on experimental canine spirocercosis, seven beagle dogs experimentally infected with 40 infectious S. lupi larvae (L(3)) were treated with doramectin. Treatment was commenced following endoscopic visualization of esophageal granulomas, and typical S. lupi eggs were detected in the feces. The treatment protocol included six treatments of doramectin (400 microg/kg subcutaneously) at 2 weeks intervals, followed by monthly injections until the disappearance of the esophageal granulomas or the end of the study (768 days post-inoculation). Eggs could not be found on fecal examinations 3-10 days after the first or second doramectin treatment. In addition, a gradual decrease in size of granulomas was noticed in all seven dogs during the course of the study. Esophageal granulomas had completely resolved in six of the seven dogs between day 35 and day 544 post-initial doramectin treatment, by day 35 in one dog (after three treatments), by day 43 in two dogs (after four treatments), by day 98 in one dog (after seven treatments), by day 460 in one dog (after 18 treatments) and by day 544 in another dog (after 21 treatments). In one dog, remnants of S. lupi granulomas could still be seen 544 days post-initiation of treatment with doramectin. Multiple subcutaneous injections of doramectin (400 microg/kg) were shown to be effective and safe in the treatment of canine spirocercosis.

Canine spirocercosis: clinical, diagnostic, pathologic, and epidemiologic characteristics.

The nematode Spirocerca lupi is a parasite of dogs with beetles of several species serving as intermediate hosts. The medical records of 50 dogs diagnosed with spirocercosis at the Hebrew University Veterinary Teaching Hospital (HUVTH) in Israel during 1991-1999 were retrospectively reviewed and compared to a control group (n=100). There was a seven-fold increase in the annual number of dogs diagnosed with spirocercosis during these years while the hospital caseload increased by 80%, indicating an emerging outbreak of this infection. Dogs from the greater Tel Aviv area were at the highest risk of being diagnosed with spirocercosis with 74% of the cases originating from this region compared to only 17% of the controls. The disease appeared to have a primarily urban pattern of distribution with a significantly higher percentage (P=0.025) of dogs from cities versus rural areas, as compared to the control group. Sixty-two percent of the cases were diagnosed during the colder months of December through April. The median age of infected dogs was 5 years, with dogs 1 year old or younger at the lowest risk of being diagnosed with spirocercosis. Large breeds were at a higher risk of infection in comparison to small breeds and the Labrador Retriever was significantly over represented (P=0.027) in the study group compared to the control population. The most common signs were vomiting or regurgitation (60%), pyrexia (24%), weakness (22%), respiratory abnormalities (20%), anorexia (18%), melena (18%) and paraparesis (14%). A caudal esophageal mass was identified by radiography in 53% of the dogs and spondylitis of the thoracic vertebrae in 33%. Fecal flotation was positive for S. lupi eggs in 80% of the dogs, and endoscopy was found to be the most sensitive diagnostic procedure and allowed diagnosis in 100% of the examined dogs. Fifty-three percent of the dogs were anemic and creatine kinase (CK) activities were elevated in 54%. Necropsy of 14 dogs revealed esophageal or gastric granulomas in 13 dogs, and an esophageal osteosarcoma in a single animal. Aortic aneurysms were found in six (43%) dogs. Out of 24, 15 dogs (63%) for which follow-up information was available died or were euthanized within 1 month of admission. The case-fatality rate decreased toward the end of the study period when improved therapy with avermectins became available.

Comparison of three enzyme-linked immunosorbant assays with the indirect immunofluorescent antibody test for the diagnosis of canine infection with Ehrlichia canis.

The aim of this study was to compare three different enzyme-linked immunosorbant assays (recombinant major antigenic protein 2 (rMAP2)-ELISA, the Immunocomb (Biogal, Israel) and the Snap 3Dx assay (IDEXX Laboratories Inc., USA)) with the indirect immunofluorescent antibody test in detecting anti-Ehrlichia canis immunoglobulin-G (IgG) antibodies. Samples tested were collected from dogs suspected to be naturally infected with E. canis and from experimentally infected dogs. When qualitative results (positive/negative) were compared, there was an overall agreement of 81% (54/67) between the indirect immunofluorescence antibody (IFA) test and the rMAP2-ELISA. An overall agreement of 94% (63/67) was found between the IFA test and the Immunocomb, and an overall agreement of 91% (61/67) was found between the IFA test and the Snap 3Dx assay. In 50 of 67 (74.6%) samples tested, complete agreement in the qualitative results was found in all four tests. Sixteen of 17 samples with disagreement in the qualitative results were found to have IFA titers of 1:320 or less. The sensitivities and specificities of the tests were found to be 0.71 and 0.85 for the rMAP2-ELISA, 0.86 and 0.98 for the Immunocomb, and 0.71 and 1.00 for the Snap 3Dx assay. The tests performed in this study were found to be highly specific in detecting E. canis antibodies. Their sensitivity was found to be low with sera having IFA titers of < or =1:320, while high with sera having titers greater than 1:320. Repeating the serological tests 1-2 weeks after the first antibody assay may overcome the sensitivity problem with titers of < or =1:320.